TAL / Tau Aggregation Inhibiting Peptide
⚠️ Disclaimer: For Research Use Only. Not for human administration or clinical therapy. Note: TAL is the general category name for Tau Aggregation Inhibiting Peptides, not one single peptide compound. Common lead candidates under this family: D-TLKIVW (TLK peptide, most widely cited), RI-AG03, ISAD1, MMD3. Below I will use D-TLKIVW (TLK) as representative for your product listing.
Basic Information (D-TLKIVW, TLK peptide, classic Tau aggregation inhibitor)
- CAS: No single registered CAS (custom research D-peptide)
- Sequence: D-Thr-D-Leu-D-Lys-D-Ile-D-Val-D-Trp (D-TLKIVW)
- Molecular Formula: \(\boldsymbol{C_{38}H_{62}N_{10}O_{8}}\)
- Molecular Weight: 786.97 g/mol
- Appearance: White to off-white lyophilized powder
- Solubility: Soluble in bacteriostatic water, aqueous buffer; moderate hydrophobicity
- Storage: Lyophilized powder stored at -20℃, protected from light and moisture. Avoid repeated freeze-thaw cycles. After reconstitution, refrigerate and use promptly.
Development Background
Tau aggregation inhibitor peptides are rationally designed D-amino acid peptides targeting Tau protein amyloid hotspots. Tau protein has two core amyloidogenic hexapeptide motifs: PHF6 (VQIVYK) and PHF6* (VQIINK). These segments drive Tau misfolding, β-sheet assembly and paired helical filament (PHF) formation, which forms neurofibrillary tangles in Alzheimer’s disease and other tauopathies. D-TLKIVW was designed based on the PHF6 motif. Using D-amino acids confers protease resistance, better stability against enzymatic degradation compared to L-peptides.
Mechanism of Action (Research Findings)
- Binds specifically to the amyloidogenic PHF6 region of Tau monomer / oligomer via hydrogen bonding and hydrophobic interaction.
- Blocks β-sheet stacking, inhibits Tau fibril nucleation and elongation.
- Suppresses formation of toxic Tau oligomers and paired helical filaments (PHF).
- D-amino acid backbone: resistant to proteases, improves stability in biological media.
- Related analog D-TLKIVWC (7-DP) can both inhibit aggregation and fragment pre-formed Tau fibrils in research models.
Research Areas
- Tau protein misfolding, oligomerization & fibrillization in vitro (ThT assay, TEM)
- Alzheimer’s disease & tauopathies research (PSP, CBD, FTDP-17)
- Tau seeding / prion-like propagation models
- Screening of Tau aggregation modulators
- Structure-activity study of amyloid inhibitor D-peptides








评价
目前还没有评价